

New Hope for Patients with Dry Macular Degeneration

Paul Vision Institute Introduces Non-Surgical Photobiomodulation (PBM) Therapy for Dry Age-Related Macular Degeneration

WILMINGTON, NC, UNITED STATES, August 21, 2026 /EINPresswire.com/ -- WILMINGTON, N.C. —

“

Photobiomodulation changes the conversation for dry AMD,” said Dr. Edward Paul. “This non-invasive treatment offers patients a proactive approach to preserving vision—and new hope.”

Dr. Edward Paul

Paul Vision Institute is offering new hope to patients with dry age-related [macular degeneration](#) (AMD) through photobiomodulation (PBM), a non-invasive light-based therapy designed to support retinal cellular function and potentially improve visual performance.

Age-related macular degeneration is a leading cause of significant vision loss among adults over age 50 and can have a profound impact on a person’s ability to read, recognize faces, drive and perform everyday activities. The dry form accounts for the majority of AMD cases. Historically, options for patients with dry AMD have largely

focused on nutritional supplementation, healthy lifestyle choices and careful monitoring for disease progression.

Photobiomodulation represents an important new approach to managing the disease.

PBM uses specific wavelengths of red and near-infrared light directed toward the retina. This therapeutic light is designed to stimulate activity within the mitochondria—the energy-producing structures within cells. Research suggests photobiomodulation may enhance cellular energy production, reduce oxidative stress and inflammation, and support healthier retinal function.

“Patients with dry macular degeneration have often been told there is little that can be done beyond taking vitamins and monitoring their condition,” said Edward L. Paul, Jr., OD, PhD, FIALVS, founder of Paul Vision Institute. “Photobiomodulation gives us another tool for helping these patients. Our goal is to preserve useful vision, improve visual function when possible and help people remain independent and active.”

Clinical research into photobiomodulation for dry AMD has produced encouraging results. Published studies have reported improvements in visual acuity and other measures of visual

function in appropriately selected patients. Unlike treatments involving injections or surgery, PBM is performed in the office, is non-invasive and requires no recovery time.

At Paul Vision Institute, patients first undergo an evaluation to determine whether they are appropriate candidates for treatment. The treatment protocol consists of nine in-office photobiomodulation treatments administered over three weeks—three treatments per week. Each session is brief, and patients can resume their normal activities immediately afterward. Visual function is monitored throughout the treatment process to assess each patient's response.

Dr. Paul emphasizes that PBM is not presented as a cure for macular degeneration, nor is it intended to replace appropriate retinal care. Instead, it provides an additional option for patients with dry AMD as part of a comprehensive approach to preserving vision and maximizing visual function.

For decades, Paul Vision Institute has specialized in helping patients with macular degeneration and other vision-threatening conditions make the best possible use of their remaining sight. In addition to photobiomodulation, the practice provides comprehensive [low vision](#) rehabilitation utilizing specialized prescription lenses, telescopic and microscopic optical systems, electronic magnification and other advanced technologies.

The combination of emerging therapies such as PBM with established low vision rehabilitation can be particularly important for people who have been told that conventional glasses or medical treatment can no longer adequately address their vision difficulties.

“Macular degeneration does not mean giving up on your vision,” Dr. Paul said. “There are more options available today than many patients realize. Advances in technology, rehabilitation and therapies such as photobiomodulation continue to create new opportunities for patients to see better and maintain their quality of life.”

Patients with dry macular degeneration who would like to learn whether photobiomodulation may be appropriate for them can contact Paul Vision Institute to schedule an evaluation.

MEDIA CONTACT

Paul Vision Institute
Phone: 910-256-6364
Dr. Edward Paul, Direct: 910-232-8250
Website: www.paulvisioninstitute.com

Edward Paul
Paul Vision Institute
+1 910-232-8250

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/935862572>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.